Lung cancer patients get a second chance: new cell combo aims to stop return of disease
NCT ID NCT07330037
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment for people with a certain type of lung cancer (non-small cell lung cancer) who had surgery but still had cancer cells left. The treatment combines a cell therapy made from the patient's own immune cells (L-TIL) with an immunotherapy drug (tislelizumab). The goal is to see if this combination can keep the cancer from coming back. About 41 participants will be enrolled in this phase 2 trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Liquid tumor-infiltrating lymphocytes (L-TIL) and tislelizumab
- What this could lead to
- If this works, it could offer a new way to prevent lung cancer from coming back after surgery in patients who didn't fully respond to initial chemo-immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 41 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?